Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC40A1 | Q9NP59 | 10/20 | 0.37 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.37 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.36 |
| ▸ | EIF2AK3 | Q9NZJ5 | 2/20 | 0.33 |
| ▸ | CLK1 | P49759 | 1/20 | 0.32 |
| ▸ | DDX3X | O00571 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30847799 | 1.00 | SLC40A1 (0.37) | SLC40A1PTGES2PTPN11EIF2AK3CLK1 | |
| SCHEMBL30847917 | 0.85 | SLC40A1 (0.41) | SLC40A1PTPN11CLK1DDX3X | |
| SCHEMBL27132412 | 0.85 | SLC40A1 (0.41) | SLC40A1PTPN11CLK1DDX3X | |
| SCHEMBL27213647 | 0.84 | SLC40A1 (0.40) | SLC40A1PTPN11EIF2AK3CLK1 | |
| SCHEMBL30847992 | 0.84 | SLC40A1 (0.40) | SLC40A1PTPN11EIF2AK3CLK1 | |
| SCHEMBL27132418 | 0.83 | SLC40A1 (0.46) | SLC40A1EIF2AK3CLK1 | |
| SCHEMBL30847889 | 0.83 | SLC40A1 (0.46) | SLC40A1EIF2AK3CLK1 | |
| SCHEMBL30847890 | 0.83 | SLC40A1 (0.46) | SLC40A1EIF2AK3CLK1 | |
| SCHEMBL30848094 | 0.83 | SLC40A1 (0.44) | SLC40A1PTPN11EIF2AK3CLK1 | |
| SCHEMBL27133421 | 0.83 | SLC40A1 (0.44) | SLC40A1PTPN11EIF2AK3CLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150321-A1 | PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY | HOTSPOT THERAPEUTICS, INC. | 2024-05-09 | — | — | US | disclosed |
| WO-2024044730-A1 | PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY | HOTSPOT THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150321-A1 | PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY | MALT1, BCL6, BCL3 | SLC40A1 1750/4885PTGES2 3001/4885PTPN11 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.